Utility of SPECT/CT in Non-Traumatic Osteonecrosis: Revisited with New Insights from a Prospective Diagnostic Study

SPECT/CT在非创伤性骨坏死中的应用:一项前瞻性诊断研究的新见解

阅读:1

Abstract

OBJECTIVES: Bone scintigraphy is a sensitive imaging method to evaluate patients with suspected osteonecrosis. We assessed the diagnostic performance of combined bone single-photon emission computed tomography/computed tomography (SPECT/CT) (CBS) in patients with known rheumatic disease or other connective tissue disorders and clinical suspicion of osteonecrosis compared to magnetic resonance imaging (MRI). METHODS: This prospective diagnostic accuracy study included 70 patients with clinical suspicion of osteonecrosis in any bone who underwent a planar triple-phase bone scan along with a regional SPECT/CT (CBS) and regional MRI. MRI was considered the standard for diagnosing the sensitivity, specificity, predictive values, and accuracy of CBS. Cohen's kappa statistic of the agreement was also calculated. RESULTS: The distribution of the patients based on the joint regions suspected to have osteonecrosis is as follows: 21 hip, 43 knee, and six ankle. MRI detected osteonecrosis in 30/70 patients. CBS had a sensitivity of 100% (30/70 were detected) and a specificity of 97% (2/40 were false positive). Overall, there was good agreement between the two scans regarding the diagnosis of osteonecrosis (Cohen's kappa statistic = 0.94). In addition to the suspected sites, CBS detected osteonecrosis in 19 additional asymptomatic sites in 13 patients. CONCLUSION: The study has demonstrated that CBS, which includes whole-body imaging and SPECT/CT, is highly sensitive in detecting osteonecrosis with accuracy comparable to regional MRI. Its inherent whole-body imaging technique enabled the detection of multifocal osteonecrosis. It can be used as an early investigating modality after routine plain radiography to establish the diagnosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。